Sugi Predict

Sugi Predict / Compounds / SCHEMBL343986

SCHEMBL343986

SCHEMBL343986

O=S(=O)(Cl)c1ccc(-c2cnco2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 1/20 0.61
▸ PKM P14618 3/20 0.56
▸ LMNA P02545 2/20 0.56
▸ GAA P10253 1/20 0.56
▸ KMT2A Q03164 2/20 0.55
▸ POLB P06746 1/20 0.55
▸ CYP3A4 P08684 2/20 0.55
▸ CYP2D6 P10635 2/20 0.55
▸ PTK2 Q05397 1/20 0.55
▸ PSEN1 P49768 1/20 0.55
▸ PSEN2 P49810 1/20 0.55
▸ APH1B Q8WW43 1/20 0.55
▸ NCSTN Q92542 1/20 0.55
▸ APH1A Q96BI3 1/20 0.55
▸ PSENEN Q9NZ42 1/20 0.55
▸ KEAP1 Q14145 1/20 0.51
▸ LTA4H P09960 1/20 0.51
▸ MEN1 O00255 1/20 0.49
▸ CYP11B1 P15538 1/20 0.46
▸ CYP11B2 P19099 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14620819 0.95 NOTUM (0.56) NOTUMPKMLMNAGAAKMT2A
SCHEMBL13836472 0.84 PKM (0.55) NOTUMPKMLMNAGAAKMT2A
SCHEMBL3095961 0.84 NOTUM (0.55) NOTUMPKMLMNAGAAKMT2A
SCHEMBL9026241 0.84 LMNA (0.59) NOTUMPKMLMNAGAAKMT2A
SCHEMBL949044 0.82 KMT2A (0.55) NOTUMPKMLMNAGAAKMT2A
SCHEMBL10768177 0.82 PKM (0.78) NOTUMPKMLMNAGAAKMT2A
SCHEMBL27712073 0.81 KMT2A (0.59) NOTUMPKMLMNAGAAKMT2A
SCHEMBL13389167 0.80 KMT2A (0.50) NOTUMPKMLMNAGAAKMT2A
SCHEMBL14969344 0.80 KMT2A (0.61) NOTUMPKMLMNAGAAKMT2A
SCHEMBL11305429 0.80 KMT2A (0.61) NOTUMPKMLMNAGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 — — US disclosed
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF MBD Co., Ltd. (KR) 2024-08-29 — — US disclosed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 — — US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 — — US disclosed
US-10364240-B2 Aryl sulfonamides ChemoCentryx. Inc. (US) 2019-07-30 — — US disclosed
EP-2888251-B1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INST (AU) 2019-04-24 — — EP disclosed
EP-3087069-B1 COMPOUNDS USEFUL AS CCR9 MODULATORS NORGINE BV (NL) 2019-01-30 — — EP disclosed
US-9969687-B2 Compounds useful as CCR9 modulators NORGINE B.V. (NL) 2018-05-15 — — US disclosed
US-9969687-B2 Compounds useful as CCR9 modulators NORGINE B.V. (NL) 2018-05-15 — — US disclosed
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-04-26 — — US disclosed
EP-1567486-A2 BIS-ARYL SULFONAMIDES Chemocentryx (US) 2005-08-31 — — EP disclosed
EP-1562940-A2 ARYL SULFONAMIDES ChemoCentryx Inc (US) 2005-08-17 — — EP disclosed
US-20050165067-A1 Aryl sulfonamides CHEMOCENTRYX 2005-07-28 — — US disclosed
US-20050137193-A1 Aryl sulfonamides CHEMOCENTREYX 2005-06-23 — — US disclosed
US-20050137179-A1 Bis-aryl sulfonamides CHEMOCENTRYX, INC. 2005-06-23 — — US disclosed
WO-2004085384-A2 BIS-ARYL SULFONAMIDES CHEMOCENTRYX (US) 2004-10-07 — — WO disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 — — WO disclosed
US-20040171654-A1 Aryl sulfonamides CHEMOCENTRYX, INC. 2004-09-02 — — US disclosed
US-20040167113-A1 Bis-aryl sulfonamides CHEMOCENTRYX, INC. 2004-08-26 — — US disclosed
WO-2004046092-A2 ARYL SULFONAMIDES CHEMOCENTRYX (US) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT NOTUM 2396/4885PKM 362/4885LMNA 760/4885
US-20240287032-A1 NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF CYP4B1, CYP4A11, CYP3A4 NOTUM 629/4885PKM 1276/4885LMNA 3776/4885
US-20050137193-A1 Aryl sulfonamides CCR9, CCR1, CCR2 NOTUM 3729/4885PKM 4614/4885LMNA 4484/4885
US-10364240-B2 Aryl sulfonamides CCR9, CCR1, CCR2 NOTUM 3729/4885PKM 4614/4885LMNA 4484/4885
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof CYP4A11, CYP4B1, CYP4A22 NOTUM 1490/4885PKM 1930/4885LMNA 1803/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT NOTUM 2347/4885PKM 354/4885LMNA 748/4885
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 NOTUM 1477/4885PKM 453/4885LMNA 2202/4885
US-20050137179-A1 Bis-aryl sulfonamides CCR2, CXCR2, CCL2 NOTUM 3341/4885PKM 4521/4885LMNA 4769/4885
US-20040167113-A1 Bis-aryl sulfonamides CCR2, CXCR2, CCL2 NOTUM 3341/4885PKM 4521/4885LMNA 4769/4885
US-20040171654-A1 Aryl sulfonamides CCR9, CCR1, CCR2 NOTUM 3729/4885PKM 4614/4885LMNA 4484/4885
US-20050165067-A1 Aryl sulfonamides CCR9, CCR1, CCR2 NOTUM 3729/4885PKM 4614/4885LMNA 4484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.